BioCentury
ARTICLE | Company News

Trevena rises after TRV130 meets in pain study

September 2, 2015 1:38 AM UTC

Trevena Inc. (NASDAQ:TRVN) gained $3.09 (52%) to $9.09 on Tuesday following news post-market Monday that TRV130 met the primary endpoint in a Phase IIb trial to treat moderate to severe acute postoper...